Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NAMS, MIRM, ARQT, BBIO, MBX, and represent 51.00% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: RAPT (+$33M), VOR (+$33M), RNA (+$26M), MNKD (+$24M), ACAD (+$18M), DYN (+$8.5M), NAMS (+$8.5M), ZLAB, XLO, IBIO.
- Started 5 new stock positions in XLO, RAPT, IBIO, VOR, MNKD.
- Reduced shares in these 10 stocks: VRNA (-$361M), KRYS (-$49M), TARS (-$36M), RARE (-$30M), BBIO (-$23M), MREO (-$19M), AKRO (-$17M), PCVX (-$17M), RVMD (-$16M), IRON (-$14M).
- Sold out of its positions in ADVM, JBIO, AKRO, ASMB, ENGN, MGNX, MREO, SLN, RARE, PCVX. VRNA, CBIO.
- Frazier Life Sciences Management was a net seller of stock by $-500M.
- Frazier Life Sciences Management has $3.7B in assets under management (AUM), dropping by 11.56%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 40 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 16.0 | $594M | 17M | 35.08 |
|
|
| Mirum Pharmaceuticals (MIRM) | 14.4 | $537M | 6.8M | 78.99 |
|
|
| Arcutis Biotherapeutics (ARQT) | 7.7 | $287M | 9.9M | 29.04 |
|
|
| Bridgebio Pharma (BBIO) | 7.3 | $271M | -7% | 3.5M | 76.49 |
|
| Mbx Biosciences (MBX) | 5.6 | $210M | 6.7M | 31.54 |
|
|
| Phathom Pharmaceuticals (PHAT) | 5.6 | $207M | 13M | 16.59 |
|
|
| Maze Therapeatics (MAZE) | 5.1 | $189M | 4.6M | 41.43 |
|
|
| Trevi Therapeutics (TRVI) | 3.4 | $128M | 10M | 12.52 |
|
|
| Krystal Biotech (KRYS) | 3.2 | $120M | -29% | 489k | 246.54 |
|
| Disc Medicine (IRON) | 2.7 | $100M | -12% | 1.3M | 79.41 |
|
| Erasca (ERAS) | 2.3 | $85M | 23M | 3.72 |
|
|
| Kalvista Pharmaceuticals (KALV) | 2.2 | $81M | 5.0M | 16.15 |
|
|
| Palvella Therapeutics Inc Ne (PVLA) | 2.0 | $76M | 722k | 104.67 |
|
|
| Avidity Biosciences Ord (RNA) | 1.9 | $71M | +57% | 983k | 72.13 |
|
| Revolution Medicines (RVMD) | 1.7 | $64M | -20% | 798k | 79.65 |
|
| Dyne Therapeutics (DYN) | 1.7 | $62M | +16% | 3.2M | 19.56 |
|
| Tarsus Pharmaceuticals (TARS) | 1.6 | $60M | -37% | 729k | 81.88 |
|
| Savara (SVRA) | 1.6 | $60M | -13% | 9.9M | 6.03 |
|
| Cytokinetics Com New (CYTK) | 1.6 | $59M | +4% | 935k | 63.54 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.4 | $51M | 378k | 134.85 |
|
|
| Lexeo Therapeutics (LXEO) | 1.2 | $44M | 4.4M | 9.93 |
|
|
| Agios Pharmaceuticals (AGIO) | 0.9 | $35M | 1.3M | 27.22 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 0.9 | $35M | +111% | 1.3M | 26.71 |
|
| Zai Lab Adr (ZLAB) | 0.9 | $34M | +16% | 1.9M | 17.64 |
|
| Rapt Therapeutics Com New (RAPT) | 0.9 | $33M | NEW | 983k | 33.87 |
|
| Vor Biopharma Com New (VOR) | 0.9 | $33M | NEW | 2.5M | 13.08 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $28M | 133k | 213.24 |
|
|
| Aura Biosciences (AURA) | 0.7 | $28M | 5.1M | 5.45 |
|
|
| Mannkind Corp Com New (MNKD) | 0.6 | $24M | NEW | 4.2M | 5.67 |
|
| Valneva Se Sponsored Ads (VALN) | 0.5 | $20M | 2.3M | 8.82 |
|
|
| Alkermes SHS (ALKS) | 0.5 | $20M | 701k | 27.98 |
|
|
| Evolus (EOLS) | 0.5 | $18M | 2.6M | 6.65 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.4 | $13M | 385k | 34.71 |
|
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.3 | $12M | 500k | 23.00 |
|
|
| Travere Therapeutics (TVTX) | 0.2 | $9.2M | -38% | 242k | 38.21 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $9.2M | 4.6M | 1.99 |
|
|
| Allogene Therapeutics (ALLO) | 0.1 | $5.3M | 3.9M | 1.37 |
|
|
| Design Therapeutics (DSGN) | 0.1 | $4.9M | -73% | 521k | 9.38 |
|
| Xilio Therapeutics (XLO) | 0.1 | $3.8M | NEW | 5.9M | 0.64 |
|
| Ibio Com New (IBIO) | 0.1 | $3.8M | NEW | 2.0M | 1.93 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2025 Q4 filed Feb. 13, 2026
- Frazier Life Sciences Management 2025 Q3 filed Nov. 14, 2025
- Frazier Life Sciences Management 2025 Q2 filed Aug. 14, 2025
- Frazier Life Sciences Management 2025 Q1 filed May 15, 2025
- Frazier Life Sciences Management 2024 Q4 filed Feb. 18, 2025
- Frazier Life Sciences Management 2024 Q3 filed Nov. 15, 2024
- Frazier Life Sciences Management 2024 Q2 filed Aug. 15, 2024
- Frazier Life Sciences Management 2024 Q1 filed May 15, 2024
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023
- Frazier Life Sciences Management 2022 Q3 filed Nov. 14, 2022
- Frazier Life Sciences Management 2022 Q2 filed Aug. 10, 2022